IDEAYA Biosciences Inc (IDYA) Opciones

IDYA range bound

https://www.oncologypipeline.com/apexonco/ideaya-socks-it-gsk

I look forward to data from the PRMT5 combo trial (AMGN's AMG-193 had single-agent activity and cleaner toxicity than first-gen versions) https://aacrjournals.org/cancerres/article/83/7_Supplement/1644/722821/Abstract-1644-Dual-inhibition-of-MAT2A-and-PRMT5

Depending on the toxicity (and activity), triplets could be tested. PRMT5 inhibition could disable mechanisms protecting cancer cells from DNA damage caused by chemotherapy, radiotherapy or PARP inhibitors http://www.cell-stress.com/researcharticles/2020a-kim-cell-stress/

IDYA new 52 week high

IDYA new 52 week high

THER STOCK CANCER GOOD NEWS

BUY Ther
.meme stock

https://www.prnewswire.com/news-releases/theralink-acquires-exclusive-landmark-immunotherapy-patent-including-biomarker-from-vanderbilt-university-301787847.html

Finally some pub. Just take something to get this moving. Now we need company to throw a pr about something to keep going.

$60 million becomes $100 offering.
Price $15 which is a lot better than $9.50 or so.
Seems like there was a lot of interest in this private placement.
We will see how it trades tomorrow.

Davis.

POS company gets $100 million and then announces public offering for $60 million.
Offering price < $10.
This is criminal.
I was watching the strange trading and realized something was fishy.
shorted at $13.50.
Will buy back at < $10. Easy money.

David.

Awesome press release, lets see where this goes with that press release. 20-22 dollars possible.

"We have made significant progress on our Phase 1/2 tissue-agnostic basket trial evaluating IDE196 in patients with solid tumors harboring GNAQ or GNA11 (GNAQ/11) mutations, including metastatic uveal melanoma (MUM), cutaneous melanoma and colorectal cancer. This clinical trial progress, considered together with recent FDA feedback providing guidance on the regulatory pathway for IDE196 for treatment of MUM, are important enabling steps to advance this clinical-stage program," said Yujiro S. Hata, Chief Executive Officer and President at IDEAYA Biosciences.
IDEAYA continues to advance its MAT2A synthetic lethality program to treat patients having tumors with MTAP deletion. The Company remains committed to the research and development of a differentiated MAT2A inhibitor that could meaningfully enhance patient outcomes across a broad range of indications. IDEAYA also continues to progress its broad pipeline of synthetic lethality programs, including Pol theta for patients having tumors with BRCA or other homologous recombination deficiency (HRD) mutations, and Werner (WRN) for patients having tumors with high microsatellite instability (MSI).
Key highlights for IDEAYA's research and development programs include:
Clinical Program IDE196
IDE196
Advanced IDEAYA's Phase 1/2 tissue-type agnostic basket trial, which was initiated in June 2019 to evaluate IDE196 in solid tumors harboring activating GNAQ/11 mutations, and is entitled "A phase 1/2 study of IDE196 in patients with solid tumors harboring GNAQ/11 mutations or PRKC fusions" (ClinicalTrials.gov Identifier: NCT03947385)
Completed enrollment in the Phase 1 dose escalation portion of the Phase 1/2 clinical trial at sites in the U.S. and Australia
Anticipate selection of the dosing regimen and initiation of the Phase 2 portion of the clinical trial by year-end 2019
Expect to introduce a tablet formulation of IDE196 in Q1 2020 for use in the Phase 2 portion of the clinical trial
Enrolled our first cutaneous melanoma patient harboring a tumor with an activating GNAQ/GNA11 mutation in October 2019, a key milestone for evaluating IDE196 in solid tumors outside of metastatic uveal melanoma (MUM)
Expanded our relationship with Foundation Medicine, participating in their Smart Trials™ program for identification of non-MUM patients having tumors with activating GNAQ/11 mutations for potential enrollment in our Phase 1/2 basket trial
Anticipate release of interim data from the Phase 1/2 basket trial in Q2/Q3 2020
Obtained FDA feedback in End-of-Phase 1 meeting in Q4 2019, providing guidance on the regulatory pathway for IDE196 for treatment of MUM
Company's proposed single-arm Phase 2 IDE196-001 clinical trial may be adequate to support an NDA seeking Accelerated Approval for IDE196 monotherapy in metastatic uveal melanoma (MUM)
The single-arm potentially registration-enabling Phase 2 clinical trial will target enrollment of 60 evaluable MUM patients
The primary endpoint is overall response rate (ORR) as determined by blinded independent central review (BICR), supported by BICR-determined duration of response (DOR) as a secondary endpoint
The 13-week GLP-compliant toxicology studies in 2 species is scheduled to initiate in November 2019, in support of FDA requirement that study results be submitted prior to enrollment of more than approximately 50 patients in the investigational arm of the clinical trial that will support a marketing application
Continued the ongoing Phase 1 clinical trial, entitled "A Phase I, multi-center, open-label, study of LXS196, an oral protein kinase C inhibitor, in patients with metastatic uveal melanoma" (ClinicalTrials.gov Identifier: NCT02601378), being conducted by Novartis
A confirmed Complete Response at the 200 mg BID dose level was observed at month 31 in one of four patients previously reported with confirmed Partial Response out of 30 total (28 evaluable) BID patients in this ongoing monotherapy arm of the Novartis clinical trial
Based on confirmation of the single arm trial design and anticipated rate of enrollment, we are anticipating submission of a New Drug Application (NDA) to the FDA in Q4 2021 to Q1 2022 for IDE196 in MUM.
Synthetic Lethality Preclinical Pipeline
MAT2A
We believe that data presented at the AACR/NCI/EORTC conference in October 2019 demonstrates clinical activity of MAT2A as a biological target in patients having tumors with MTAP deletion.
Continuing our preclinical evaluation of potential drug candidates, including in the HCT116 engineered in-vivo model, and in multiple endogenous in-vivo models
Goal is to select a MAT2A inhibitor development candidate in the first half of 2020 with differentiated properties relative to Agios' presented published compounds and Agios' publicly-disclosed properties of AG270
Expect to file an IND for a differentiated MAT2A inhibitor development candidate in second half of 2020
"We continue to aggressively progress our programs, expand our capabilities and enhance our team. IDEAYA remains committed to its vision of improving lives through transformative precision medicines, and believes that the IDE196 tissue-type agnostic basket trial and our pipeline of synthetic lethality programs are key elements of this goal," said Yujiro S. Hata, Chief Executive Officer and President at IDEAYA Biosciences.
Corporate Updates
IDEAYA anticipates that existing cash, cash equivalents and short-term marketable securities of $109.4 million (as of September 30, 2019) will be sufficient to fund planned operations into the third quarter of 2021.
Financial Results
As of September 30, 2019, IDEAYA had cash, cash equivalents and short-term marketable securities totaling $109.4 million. This compared to cash, cash equivalents and short-term marketable securities of $90.0 million at December 31, 2018. The increase was primarily due to the receipt of $50.2 million in net proceeds from IDEAYA's initial public offering, which was completed in May 2019, offset by cash used in operations.
Research and development expenses for the three months ended September 30, 2019 totaled $8.9 million compared to $12.5 million for the same period in 2018. The decrease was primarily due to license fees for our IDE196 license agreement with Novartis during the three months ended September 30, 2018, offset by an increase in costs in connection with IDEAYA's Phase 1/2 clinical trial to evaluate IDE196 in solid tumors, and costs for personnel, consulting, and laboratory supplies in support of our research programs during the three months ended September 30, 2019.
General and administrative expenses for the three months ended September 30, 2019 totaled $2.7 million compared to $1.1 million for the same period in 2018. The increase was primarily due to an increase in costs for personnel, directors' and officers' liability insurance premiums, and professional fees in connection with becoming a publicly traded company as well as external legal patent expenses for our product candidates.
The net loss for the three months ended September 30, 2019 was $11.0 million compared to $13.0 million for the same period in 2018. Total stock compensation expense for the three months ended September 30, 2019 was $0.5 million compared to $0.3 million for the same period in 2018.

IDEAYA anticipates that existing cash, cash equivalents and short-term marketable securities of $109.4 million (as of September 30, 2019) will be sufficient to fund planned operations into the third quarter of 2021.

has anyone bought except me? big day today

spec. buy